Valued at USD 9.34 billion in 2024, the osteoarthritis market is projected to reach USD 10.12 billion in 2025 and USD 21.22 billion by 2034, growing at a CAGR of 8.6% during the forecast period 2025–2034. Rising elderly populations, advances in diagnostic technology and increased spending on healthcare infrastructure are fueling expansion, while high development costs continue to limit growth. Key players across pharmaceuticals and orthopedics are positioning for this long-term opportunity.

Hospital Pharmacies Anchor Distribution

By distribution channel, the osteoarthritis market is segmented into hospital pharmacies, retail pharmacies, drug stores and e-commerce. Hospital pharmacies held the biggest share and are expected to maintain a significant revenue share, owing to the large number of patients seeking osteoarthritis treatment in hospitals, the extensive selection of medicines stocked and the simplicity with which purchases can be reimbursed. For suppliers, hospital formulary access therefore remains a decisive commercial lever. Hospital pharmacies also benefit from rising patient footfall in hospital premises.

Route of Administration: Parenteral, Topical and Oral

The market is also segmented by route of administration into parenteral, topical and oral. Polaris notes that osteoarthritis pain is frequently treated with topical, oral and injectable analgesics, and that the acceptance of pain drugs is significant because of administration convenience and price. The topical route offers a noninvasive option alongside orthopedic braces, while parenteral products such as viscosupplementation and extended-release injectables address more targeted joint-level relief.

Browse Insights:

https://www.polarismarketresearch.com/industry-analysis/global-osteoarthritis-market

Assistive Devices Within Treatment Type

Under treatment type, assistive devices form the second major category beside drugs. Alternative drugs, physical therapy and supportive equipment are currently available to treat pain and enhance joint function. Zimmer Biomet Holding and Abbott Laboratories Incorporation appear among the named participants, reflecting the overlap between pharmaceutical and device-oriented players. As the senior population grows, demand for supportive solutions that complement drug regimens is expected to remain relevant. Supportive equipment and physical therapy sit alongside drugs as non-surgical options.

Biomarkers and Personalized Treatment

Personalized osteoarthritis drugs have been conceptualized as a significant improvement in the diagnosis, treatment and monitoring of disease severity. Biomarkers with easy measurement, acceptable sensitivity and specificity, and methodologies interpretable by doctors are critical for clinical value. Using biomarkers to identify individuals most likely to respond to particular therapies may boost response rates and reduce exposure to medicines that are unlikely to work or may cause harmful side effects. Combining distinct biomarkers with baseline characteristics such as age and gender may tailor plans even further.

Disease-Modifying Therapy and Pipeline Momentum

Pipeline activity centers on potential disease-modifying therapy. Novartis stated in September 2021 that LNA043 received fast-track designation from the U.S. FDA for knee osteoarthritis; the candidate is being developed as a potentially first-in-class option. Drugs for severe illnesses with unmet medical needs can be developed and evaluated more quickly under such designations. In July 2025, Johnson & Johnson MedTech and Pacira BioSciences announced a strategic agreement to expand the Early Intervention portfolio for knee osteoarthritis with ZILRETTA.

AI and Government Support

AI is expected to enable earlier, more accurate diagnosis and to accelerate drug discovery, clinical trial support and therapeutics development by screening candidates more efficiently, while expanding telehealth and digital health. Osteoarthritis increasing government spending on cell-based research further boosts the market. These dynamics place diagnostics vendors, drug developers and digital health providers in a shared growth ecosystem within the osteoarthritis market.

Competitive Landscape

The report profiles ABIOGEN PHARMA S.p.A, Assertio Therapeutics, Inc., Abbott Laboratories Incorporation, Apotex Inc., Ampio Pharmaceuticals Inc., Bayer AG, Eli Lilly and Company, Horizon Therapeutics plc, Johnson & Johnson, Merck Sharp & Dohme Corp., Mylan N.V., Novartis AG, Pfizer Inc., Reckitt Benckiser Group PLC, Sanofi SA, Tolmar Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd. and Zimmer Biomet Holding as key players. Growth drivers cited in the report include higher healthcare infrastructure spending, a rising elderly population and advances in diagnostic technology.

More Trending Latest Reports By Polaris Market Research:

ai-chip-startups-challenging-nvidia-the-rise-of-inference-ai-custom-silicon-and-next-gen-accelerator

dicyclopentadiene-market

personal-protective-equipment-market

sportswear-industry-trends

japan-ocean-economy-market

cross-border-b2c-e-commerce-market

regenerative-meat-market

how-smart-home-automation-us-shaping-future-of-living

loyalty-management-market